Clinical Trials Browser

Neoplasms × Rituximab × 1 year × Clear all

NCT00092222 2026-04-14

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

NCT05283720 2026-04-13

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

496 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06191744 2026-04-13

EPCORE™FL-2

Phase 3 Recruiting

1,095 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT03467867 2026-04-06

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

Phase 2 Active not recruiting

25 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoproliferative Disorders, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04529772 2026-03-31

ESCALADE

Phase 3 Active not recruiting

611 enrolled

Lymphoid

Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06031233 2026-03-30

MINUTE

Phase 4 Recruiting

776 enrolled

Tumor-Agnostic

Neoplasms

NCT01804712 2026-03-12

Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy

Phase EARLY_PHASE1 Completed

8 enrolled 12 charts

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT04268277 2026-02-27

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Phase 2 Terminated

22 enrolled 20 charts

Lymphoid

Neoplasms, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT04421560 2026-02-20

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Phase 1/2 Recruiting

37 enrolled

Neoplasms, Recurrence

NCT03943901 2026-01-29

Split-Dose R-CHOP for Older Adults With DLBCL

Phase 2 Active not recruiting

27 enrolled 11 charts

Lymphoid

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT00006436 2025-12-30

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

Phase 2 Completed

68 enrolled 24 charts

Lymphoid

Acquired Immunodeficiency Syndrome, Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, AIDS-Related

NCT05099471 2025-11-28

VIWA-1

Phase 2 Recruiting

80 enrolled

Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia, Neoplasms

NCT05267054 2025-09-15

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

Phase 1/2 Completed

53 enrolled 17 charts

Lymphoid

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT03013218 2025-08-01

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

Phase 1 Completed

174 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms

NCT05409066 2025-07-28

EPCORE FL-1

Phase 3 Active not recruiting

549 enrolled 5 FDA

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms